Symbicort SMART Satisfaction From Patient Perspective 2009
Launched by ASTRAZENECA · Jul 24, 2009
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have been prescribed Symbicort SMART (1 or 2 inhalation twice daily) by their Dr's for the past 3 months
- • Informed consent
- Exclusion Criteria:
- • Symbicort SMART treatment \< 3 months
- • Patients requiring short courses of oral steroids more than twice in a month
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Petaling Jaya, Selangor, Malaysia
Patients applied
Trial Officials
Liam Chong Kin, Professor
Principal Investigator
UMMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials